dr. singh on potential implications of the imvigor130 trial in bladder cancer
Published 4 years ago • 67 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
1:34
dr. singh on patient selection for immunotherapy in bladder cancer
-
0:16
copy of dr. singh on the role of chemotherapy in bladder cancer
-
2:19
dr. galsky discusses the rationale for the imvigor130 study in bladder cancer
-
1:11
dr. singh on the role of chemotherapy in bladder cancer
-
0:58
dr. singh on combination therapy in localized bladder cancer
-
0:52
dr. singh on investigational immunotherapy combinations in urothelial cancer
-
2:18
final os results of imvigor130: 1l atezolizumab /- chemotherapy in metastatic urothelial carcinoma
-
1:21
dr. singh on the prevalence of genomic testing in urothelial cancer
-
4:20
imvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
-
2:57
phase 3 imvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma
-
5:27
imvigor130: atezolizumab with or without chemotherapy in metastatic urothelial cancer
-
0:48
imvigor130: 1l atezolizumab /- chemotherapy in metastatic urothelial carcinoma
-
2:03
the evolution of bladder cancer treatment and the immuno-oncology era
-
0:49
how can ai and machine learning influence treatment decisions in bladder cancer?
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
2:20
the role of erdafitinib in treating patients with bladder cancer
-
1:21
dr. o’donnell on pd-l1 testing in bladder cancer
-
0:54
dr. o’donnell on challenges with pd-l1 testing in bladder cancer
-
1:26
dr linscott on future directions for utdna research in bladder cancer